Telix Pharmaceuticals Ltd — Capital/Financing Update 2019

Aug 18, 2019

==> picture [142 x 79] intentionally omitted <==

Telix Pharmaceuticals announces results of successful SPP

Melbourne (Australia) – 19[th] August 2019. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (“MTR”) is pleased to advise that, at closing on Friday 16[th] August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totalled approximately $9.6 million.

Following the successful completion of an AUD $40.0 million private placement to professional and sophisticated investors announced on 17[th] July 2019, the Company announced an SPP to offer existing shareholders the opportunity to purchase up to AUD $15,000 worth of new shares at the same price as the Placement ($1.30 per share) and without any brokerage or transaction costs.

The SPP was capped at a maximum of $5 million worth of new shares.

As the SPP is over-subscribed, a scale-back of applications will be enacted. The Company’s scaleback policy is that all validly received applications will be scaled-back equally by approximately 47%.

New shares are expected to be issued to investors under the SPP on Thursday 22[nd] August 2019.

Refunds are expected to be paid by direct credit (for those shareholders who have provided the Company with their bank details) or cheque on or around 28[th] August 2019. No interest will be paid on refunds.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Liège (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

---

Telix Corporate Contact Telix Investor Relations Dr Christian Behrenbruch Lisa Wilson Telix Pharmaceuticals Limited In-Site Communications CEO Tel: +1 212 452 2793 Email: chris@telixpharma.com Email: lwilson@insitecony.com

Page 1

TEL005_1900178_025.DOCX

==> picture [142 x 79] intentionally omitted <==

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

Page 2

TEL005_1900178_025.DOCX